 Part A: Single Ascending Dose study of AMAZ-02 with 3 cohorts each cohort n8 subjects, total n24 subjects. Cohorts undergo two periods of single dose intervention separated by 3 week washout. Adverse events, clinical biochemistry for safety assessment and plasma and urine collected for pharmacokinetic measurement for parent and metabolite levels in circulation. 